On November 10, 2022 Provectus (OTCQB: PVCT) reported that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer immunotherapy PV-10, an intratumoral formulation of Provectus’ small molecule rose bengal sodium (RBS), and immune checkpoint inhibitor KEYTRUDA (pembrolizumab) for the treatment of Stage III cutaneous melanoma will be presented at Melanoma Bridge 2022, to be held in Naples, Italy and online from December 1-3, 2022 (Press release, Provectus Biopharmaceuticals, NOV 10, 2022, View Source [SID1234623762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract accepted for video oral communication and poster presentation is entitled "Response for combination of PV-10 autolytic immunotherapy and immune checkpoint blockade in stage III cutaneous melanoma."